Race Oncology shares rise 15% after positive RC220 bisantrene formulation results, nearing human trials.

Race Oncology Ltd shares soared 15% on the ASX after the company announced positive results for its RC220 bisantrene formulation. The biopharmaceutical company is using RC220 to target unmet medical needs across multiple oncology indications. Good Laboratory Practice (GLP) studies for RC220 bisantrene have been completed, bringing the company closer to human trials.

Articles

The Motley Fool Australia

Proactive Investors Australia

Proactive Investors

Proactive Investors

-- show less --

Further Reading

Related Stories